Vancouver, BC - TheNewswire - January 12, 2023 - Izotropic Corporation (“Izotropic” or the “Company”) (CSE:IZO) (OTC:IZOZF) (FSE:1R3), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that it has created a compensation committee (the “Compensation Committee” or the “Committee”) to review and make recommendations to the Board of Directors on matters of compensation.

The Compensation Committee will assist in evaluating and compensating named executive officers, executive officers, and consultants; assist in identifying, assessing, and managing risks associated with compensation policies; and identify and discuss with the Board succession and resource planning risks, including ensuring that executive compensation is adequate to attract, motivate and retain competent executive personnel; and ensure that executive compensation is directly and materially related to operating performance and aligned with the short-term and long-term objectives of the Company and its shareholders.

The Board has adopted a Compensation Committee Charter detailing the roles and responsibilities of the Committee, composition, meeting framework, resources and authority, and undertakings in order to carry out its oversight capabilities.

The Compensation Committee is comprised of three appointed members: Mr. Ali Sodagar, Mr. Ralph Proceviat, and Mr. Alex Tokman.

ON BEHALF OF THE BOARD

Investor Relations Contact:

Mr. James Berard

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Toll Free: 1-833-IZOCORP ext.1

Media Inquiries Contact:

Ms. Jaclyn Thast

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Toll Free: 1-833-IZOCORP ext.3

About Izotropic Corporation

Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.